CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial Ticagrelor versus clopidogrel in patients with acute coronary syndromes Genotyping to Guide Clopidogrel Treatment: An In-Depth Analysis of the TAILOR-PCI Trial P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trial Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysis 1-Year Outcomes of Delayed Versus Immediate Intervention in Patients With Transient ST-Segment Elevation Myocardial Infarction Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study

Editorial01 July 2020

JOURNAL:Eur Heart J. Article Link

Identifying coronary artery disease patients at risk for sudden and/or arrhythmic death: remaining limitations of the electrocardiogram

B Asatryan, L Roten, T Reichlin et al. Keywords: sudden death; arrhythmic death; electrocardiogram; CHD

ABSTRACT

The important study concerning the easy-to-use electrocardiogram (ECG) markers of sudden and/or arrhythmic death (SAD) in coronary artery disease (CAD) patients as presented by Chatterjee et al.1 is a weighty contribution to an intricate and still rather puzzling topic. They implicate that in CAD patients, contiguous Q waves, left ventricular hypertrophy (LVH), QRS duration, and JTc prolongation provide incremental predictive value beyond traditional risk factors for SAD. While this study is unique in providing easily measurable markers that improve SAD risk stratification, it also...